Hoth Therapeutics, Inc. (HOTH), Tuesday announced positive data from its HT-VA study, evaluating the effects of parenteral Glial Cell-Derived Neurotrophic Factor or GDNF in a diet-induced obesity and metabolic-associated fatty liver disease or MAFLD model.
The findings revealed highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction.
Additionally, the study showed that GDNF directly targets the biological mechanisms responsible for fat accumulation in the liver.
Backed by these positive findings, the company plans to advance HT-VA data into additional preclinical validation studies, evaluate clinical development pathways for metabolic and liver diseases, and explore strategic partnerships and collaborations to accelerate development.
In the pre-market hours, HOTH is surging 42.94 percent, to $0.7317 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.